PVRI 2023/24 Digital: Breaking barriers in pulmonary hypertension

Next session:

8 November 2023

  • days
  • Hours
  • Minutes

PVRI 2023/24 Digital is a monthly webinar series of cutting edge science

We are delighted to introduce our new webinar series, PVRI 2023/24 Digital, launching November 2023. The series follows the success of our PVRI 2021/22 series and has been developed by Dr Patricia Thistlethwaite MD, PhD, University of California San Diego.


The monthly webinars will take place on the second Wednesday of each month at 15:00 BST/GMT and will feature keynote talks from senior experts in the field as well as young investigators. In addition to our in-person meetings and symposia, this series will enable us to connect with our worldwide community, but also allow us to continue to explore and discuss important new research. During the live sessions, there will be ample time set aside for Q&A to encourage active participation from our audience. 

Scientific programme

PAH Risk Calculators – State of the Art Assessment

8 November 2023, 3PM GMT


  • Improving accuracy in prognosis in PAH Prognostic Scoring Systems – REVEAL 2.0 onwards Raymond Benza
  • Integration of mutational profile into PAH Risk Calculators for better assessment of prognosis Eric Austin
  • Integration of biomarkers into PAH Risk Calculators for better assessment of prognosis Anna Hemnes

Controversies in Chronic Thromboembolic Pulmonary Hypertension: Pro-Con Debate

13 December 2023, 3PM GMT


  • Pro-con: All patients should have balloon pulmonary angioplasty before being referred for pulmonary endarterectomy
  • Pro-con: Anticoagulation should be used lifelong after pulmonary endarterectomy
  • Pro-con: Pulmonary hypertension recurs after pulmonary endarterectomy in most patients

Clinical Trials for Pulmonary Arterial Hypertension: What are we learning?

10 January 2024, 3PM GMT


  • ADVANCE Trial – Ralinepag – prostacyclin receptor agonist Fernando Torres 
  • Sotatercept phase 2 and phase 3 trials Mark Humbert 
  • TORREY Trial – Inhaled Seralutinib (PDGFR, CSFIR, c-Kit inhibitor) Robert Frantz 
  • VIPAH-PRN Trial – Vardenafil inhaled phosphodiesterase type-5 inhibitor powder Veronica Franco 
  • More TBC

Enhancing Drug Development for Paediatric Pulmonary Hypertension: An Integrative Perspective

14 February 2024, 3PM GMT


  • Clinical challenges in developing drug therapies for children with pulmonary hypertension 
  • Challenges related to drug approval for children with pulmonary hypertension – regulatory perspective
  • Challenges facing pharmaceuticals in drug development for paediatric pulmonary hypertension
  • Utility of Paediatric Registries for the characterization of pulmonary hypertensive phenotypes

Ion Channels: Pathogenic Role and Therapeutic Intervention in Pulmonary Arterial Hypertension

13 March 2024, 3PM GMT


  • Mechanosensitive cation channels in the pulmonary vascular wall in pulmonary arterial hypertension
  • KCNK3 and ABCC8 Mutations in pulmonary vascular disease
  • Proton exchangers in pulmonary smooth muscle cells in pulmonary arterial hypertension
  • Pathophysiologic role of mutant potassium channels in pulmonary hypertension
  • Targeting KATP channels for treatment of pulmonary arterial hypertension

Single Cell Transcriptional Profiling in Lung Health and Pulmonary Arterial Hypertension

10 April 2023, 3PM BST


  • Update on the Human Lung RNAseq Atlas
  • Unsupervised transcriptomic profiling of whole blood shows biologic heterogeneity in iPAH
  • Cellular landscape atlas of pulmonary endarterectomy tissue using single cell RNAseq
  • Single cell RNAseq identifies cellular abnormalities in rodent models of pulmonary hypertension
  • Single-cell transcriptomic profiles of pulmonary artery endothelial cells in health and pulmonary arterial hypertension. 

More webinars to be announced soon!

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI